Table 4.
Drugs targeting more than or equal to two common susceptibility genes. Black-bordered letters represent drugs targeting more than or equal to two hub common susceptibility genes.
| Drug | Target gene | Effect |
|---|---|---|
| Amoxicillin | HLA-DQB1, HLA-DRA, HLA-DRB5 | Antibacterial |
| Aspirin | HLA-DPB1, HLA-DQB1 | NSAID |
| Clavulanic acid | HLA-B, HLA-DQB1, HLA-DRA, HLA-DRB5 | β-lactamase inhibitor |
| Clozapine | HLA-DPB1, HLA-DRB5 | Antipsychotic |
| Filgotinib | JAK1, TYK2 | JAK inhibitor, Anti-inflammatory |
| Floxacillin | HLA-B, HLA-DQB1, HLA-DRA | Antibiotic |
| Lumiracoxib | HLA-DQA1, HLA-DQB1 | NSAID |
| Tofacitinib | JAK1, TYK2 | JAK inhibitor |
| Aldesleukin | IL2RA, CD28, SOCS1, STAT4 | Recombinant analog of IL-2 |
| Arsenic trioxide | MAPK1, MAPK3 | Chemotherapeutic |
| Baminercept | LTBR, TNFSF14 | Antirheumatic |
| Belatacept | CD86, CD28 | Selective costimulation modulator, |
| Antirheumatic, Immunosuppressant | ||
| Briakinumab | IL12B, IL12A | Anti-IL-12 antibody |
| Fostamatinib | JAK1, CAMK2G, LCK | Spleen tyrosine kinase inhibitor |
| Leucovorin | GATA3, RUNX3 | Folic acid analogs |
| Mercaptopurine | GATA3, HLA-DQA1 | Antineoplastic |
| Methotrexate | SLAMF1, TNFAIP3 | Antineoplastic |
| Purvalanol | MAPK1, MAPK3 | MAPK1, MAPK3 inhibitor |
| Ruxolitinib | JAK1, IL7R | JAK1/2 inhibitor, Antineoplastic |
| Seliciclib | MAPK1, MAPK3 | CDK inhibitor |
| Ulixertinib | MAPK1, MAPK3 | ATP-competitive ERK1/2 inhibitor |
| Ustekinumab | IL12B, IL12A, TNFAIP3 | Anti-IL12/IL23 antibody |